Allstate Corp Buys Shares of 21,090 Edwards Lifesciences Corporation $EW

Allstate Corp bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 21,090 shares of the medical research company’s stock, valued at approximately $1,640,000.

Other institutional investors also recently added to or reduced their stakes in the company. NorthCrest Asset Manangement LLC raised its stake in shares of Edwards Lifesciences by 56.8% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 6,731 shares of the medical research company’s stock worth $516,000 after buying an additional 2,439 shares in the last quarter. Florida Trust Wealth Management Co lifted its position in Edwards Lifesciences by 19.4% in the 3rd quarter. Florida Trust Wealth Management Co now owns 8,678 shares of the medical research company’s stock worth $675,000 after buying an additional 1,411 shares in the last quarter. Smithbridge Asset Management Inc. DE increased its position in Edwards Lifesciences by 3.0% in the 3rd quarter. Smithbridge Asset Management Inc. DE now owns 15,710 shares of the medical research company’s stock worth $1,222,000 after purchasing an additional 455 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Edwards Lifesciences by 45.5% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,702 shares of the medical research company’s stock valued at $832,000 after acquiring an additional 3,349 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its stake in shares of Edwards Lifesciences by 2.0% in the 3rd quarter. Maryland State Retirement & Pension System now owns 28,530 shares of the medical research company’s stock valued at $2,219,000 after purchasing an additional 556 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 57,824 shares of company stock worth $4,863,323 in the last quarter. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on EW shares. UBS Group reissued a “neutral” rating and issued a $95.00 price objective (up from $92.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Wells Fargo & Company set a $100.00 target price on shares of Edwards Lifesciences in a report on Thursday, December 18th. Barclays reissued an “overweight” rating and set a $104.00 target price (up previously from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Truist Financial set a $92.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.82.

Edwards Lifesciences Stock Down 1.1%

NYSE:EW opened at $83.40 on Wednesday. The company has a market cap of $48.40 billion, a price-to-earnings ratio of 35.95, a P/E/G ratio of 3.24 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock’s fifty day moving average price is $85.09 and its two-hundred day moving average price is $80.69. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.